Why formulation and analytical science should shape medicines infrastructure

Start with the product question

ICH Q8 Pharmaceutical Development describes systematic development through product and process understanding. It covers the intended use of the product, material attributes, excipient function, critical quality attributes, experimental work, manufacturing process development and control strategy.

The practical lesson for infrastructure planning is that a formulation environment should not be designed as an isolated room full of instruments. It should support a sequence of questions about materials, composition, process, measurement and performance.

This does not mean a building can be declared compliant with Q8. It means the technical brief should reflect the type of evidence that sound pharmaceutical development needs to generate.

Analytical science is decision infrastructure

ICH Q14 Analytical Procedure Development describes science- and risk-based analytical development, including intended purpose, performance, robustness and life-cycle management.

An analytical procedure is valuable because it supports a decision with suitable evidence. That should shape the proposed relationship between sample receipt, preparation, instrumentation, data review, method understanding, reference materials, controlled records and later transfer.

The design must also recognise that not every analytical need should sit inside one organisation. Specialist testing, independent work and rare equipment may remain external. The operating model should define what must be controlled internally, what may be accessed through qualified providers and how evidence crosses that boundary.

Risk should shape the level of control

ICH Q9 Quality Risk Management states that risk evaluation should be based on scientific knowledge and linked to patient protection, with effort, formality and documentation proportionate to risk.

For campus planning, this supports a disciplined hierarchy. High consequence activities may require stronger segregation, environmental control, data governance, review and recovery. Lower risk exploration may benefit from flexibility. The answer should follow the work and its risks, not the visual language of a finished pharmaceutical plant.

Digitalisation can reduce some risks and introduce others. Connected instruments, automated transfer and analysis can improve consistency, but they also create questions about data integrity, configuration, cybersecurity, failure modes and human review.

Quality is a life-cycle system

ICH Q10 Pharmaceutical Quality System brings together knowledge management, quality risk management, process and product monitoring, corrective and preventive action, change management and management review across the product life cycle.

That has a direct architectural implication. Quality is not only a department or archive. It affects how work is observed, how records are controlled, how deviations are investigated, how changes are authorised and how learning returns to development.

A future VARUNÉ environment would therefore need clear data ownership, review points, controlled flows and accountable roles before it could claim operational quality. A concept illustration cannot prove any of those things.

From development to future process learning

ICH Q13 Continuous Manufacturing addresses the development, implementation, operation and life-cycle management of continuous manufacturing. It also recognises that changes in scale or integration can change system behaviour and require fresh risk assessment.

The relevant principle is caution through transition. Knowledge generated at one scale does not automatically prove control at another. A proposed pilot environment could be designed to support process learning and transfer planning, but that would not make it a commercial manufacturing facility.

In the United Kingdom, making or assembling human medicines generally requires the appropriate MHRA manufacturer licence and compliance with the applicable standards. The MHRA manufacturer licence guidance should therefore sit above any future manufacturing claim.

The proposed VARUNÉ Labs approach

The current concept reserves a proposed environment for formulation and analytical science, connected conceptually to translational development and a possible later pilot environment.

Before that concept advances, the project should define users, work types, containment needs, sample and material flows, analytical requirements, data architecture, equipment ownership, maintenance, calibration, quality oversight, external provider interfaces and the licence boundary.

The strongest design may not contain every instrument or process. It may be the one that keeps core decisions close, uses qualified external capability where sensible and expands only when repeated demand supports ownership.

Conclusion

Good medicines infrastructure begins with the evidence it must create and protect. Formulation, analytical science, risk management and life-cycle quality provide a more durable design language than equipment lists.

For VARUNÉ Labs, that language is a framework for future decisions. It is not evidence that a laboratory, product, process or regulated capability already exists.